Compositions and methods for treating neural pathologies are provided. In particular, compositions and methods for treating neural pathologies including axonal degeneration are provided. The compositions include peptide α-ketomides optionally in combination with a second therapeutic agent. Another aspect of the invention provides compositions and methods for treating hyperproliferative disorders. Exemplary compositions for treating hyperproliferative disorders include an anti-proliferative agent such as paclitaxel in combination with a calpain inhibitor such as AK295.

6 Claims, 13 Drawing Sheets
Figure 1

Figure 2
Figure 4
Figure 5
Figure 6
Figure 8
Figure 9
Figure 10
Figure 11

A (control)

C (STZ+insulin)

E (STZ+insulin + AK 295)

B

D

F

x20

x100
Figure 12

A

Length of axons (mm)

Control 200mM 250mM 300mM

B

Area of DRG halo (mm²)

Control 200mM 250mM 300mM
Figure 13

8 Days after treatment
Top: control
middle: glucose 300mM + AK 295 µM
bottom: glucose 300mM
Figure 14
KETOAMIDE INHIBITORS IN CHRONIC NERVE DISEASE

CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority to U.S. Provisional Patent Application No. 60/413,506 filed on Sep. 25, 2002, which is incorporated herein in its entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

Aspects of the work described herein were supported by Public Health Services grant Nos. 1 R01 GM61964 and 5 P01 NS40405-03 from the National Institutes of Health. Therefore, the U.S. government has certain rights in the invention.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates generally to the use of calpain inhibitors, in particular to methods for the treatment of peripheral axonal degeneration. Other aspects of the invention relate to the use of peptide α-ketoamide compounds to treat pathological conditions including neural pathologies, and combinations of anti-hyperproliferative agents with peptide α-ketoamides for the treatment of hyperproliferative conditions.

2. Related Art

Peripheral neuropathy is a major dose-limiting complication of commonly used anti-cancer agents, including vincristine, cisplatin, and paclitaxel (Taxol®). Paclitaxel, a microtubule toxin derived from the western yew tree, is particularly effective against solid tumors, but causes a predominantly sensory neuropathy that may be severe enough to necessitate cessation of treatment. The neuropathy is characterized by degeneration of sensory axons, manifesting clinically as numbness, pain, and loss of balance [Lipton, R. B., Apfel, J. P. Dutcher, R. Rosenberg, J. Kaplan, A. Berger, A. I. Einzig, P. Wiemik and H. H. Schaumburg (1989). “Taxol produces a predominantly sensory neuropathy.” Neurology 39 (3): 368-73]. Paclitaxel causes a similar sensory neuropathy in rodents that provides a useful experimental model for the treatment of peripheral neuropathies.

Calpains are ubiquitous cytosolic proteolytic enzymes involved in both physiological and pathological cellular functions. They are calcium-dependent enzymes belonging to the family of cysteine proteases. Limited activation of calpains results in modification or activation of protein receptors, enzymes, and cytoskeletal proteins. Pathological cellular insults lead to more generalized calpain activation, resulting in cytoskeletal degradation and cell death.

Calpain activation likely occurs due to sustained elevation of intracellular calcium that is a common feature of models of neuronal injury [Bartus, R. (1997). “The calpain hypothesis of neurodegeneration: evidence for a common cytotoxic pathway.” Neuroscientist 3: 314-327]. Thus, there is a need for compositions and methods of treating pathologies related to calpain activation.

Because neuronal pathologies, in particular neuropathy, can have a dramatic impact on quality of life of patients, there is also a need for compositions and methods for treating these disorders, in particular, compositions and methods for treating pathologies with little or reduced side effects such as neuropathy.

There is still another need for methods and compositions for treating axonal degeneration.

SUMMARY OF THE INVENTION

Aspects of the present invention are directed to compositions containing calpain inhibitors, preferably peptide α-ketoamides, and methods of their use for the treatment of a pathology, for example pathologies of the peripheral nervous system such as neuropathy, axonal degeneration, or calcium-induced cell injury. It has been discovered that the systemic administration of the peptide α-ketoamides, including for example AK295, is an effective treatment for calpain related pathologies, in particular, axonal degeneration and peripheral neuropathy.

Another aspect of invention provides pharmaceutical compositions for the treatment of hyperproliferative disorders including an anti-hyperproliferative agent, for example a microtubule stabilizing agent for the treatment of the hyperproliferative disorder, in combination with a calpain inhibitor such as a peptide α-ketoamide to limit or reduce side effects of the anti-hyperproliferative agent such as peripheral neuropathy or cytoskeletal degeneration of sensory neurons. Exemplary anti-hyperproliferative agents include microtubule stabilizing agents such as paclitaxel, also referred to as Taxol®. Exemplary calpain inhibitors include peptide α-ketoamides, for example peptide α-ketoamides of formula I.

Additional aspects of the invention are directed to methods for the prevention of behavioral, electrophysiological, and pathological effects of microtubule stabilizing agents by administering a peptide α-ketoamide to a host, for example to a host having microtubule-stabilizing-agent-induced behavioral, electrophysiological, and pathological effects. The structure of an exemplary peptide α-ketoamide, AK295, is shown below.

Pathologies including but not limited to paclitaxel-induced axonal degeneration can be treated by administering a peptide α-ketoamide to a host either alone, or in combination with other therapeutic agents, for example anti-inflammatory agents, or anti-hyperproliferative agents.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a diagram showing an exemplary injection schedule of paclitaxel and AK295.

FIG. 2 is a line graph showing dose-dependent axonal degeneration in DRG cultures. Note that control cultures continue to grow (inset) while those exposed to paclitaxel demonstrate either slowed growth (5 ng/ml, inset) or progressive axonal death.

FIGS. 3A-F are photomicrographs of nerve fiber pathology. A) control dorsal root; B) ventral root from paclitaxel-treated mouse; C) dorsal root, paclitaxel, 3 weeks; D) dorsal root, paclitaxel and AK295, 3 weeks. E) dorsal root, paclitaxel, 6 weeks; F) dorsal root, paclitaxel and AK295, 6 weeks. Note that the ventral root is unaffected and that the AK295-treated animals show significantly fewer degenerating fibers. All photomicrographs×60.
FIGS. 4A-C are line graphs showing clinical characteristics of animals treated with paclitaxel, paclitaxel+AK295, and controls. Data are plotted as % change as compared to pre-treatment values. SNAP=tail sensory nerve action potential amplitude. (*p<0.05).

FIGS. 5A-D are graphs showing quantitative data of dorsal roots. Panels A and B show the distribution of remaining nerve fibers by fiber diameter, and panels C and D show the percentage of fibers lost in each size group. Note that the number of small fibers decreases with age, reflecting axonal growth.

FIGS. 6A-B are bar graphs showing paclitaxel-mediated calpain activation in PC12 cells. Panel A shows time-dependent increase in calpain activity in response to 10 ng/ml paclitaxel. Panel B shows dose-dependent calpain activation at 24 hours. Calpain activation is suppressed by addition of 50 µM AK295. AMC concentration is a direct measure of calpain activity.

FIGS. 7A-D are confocal images of PC12 cells stained with antibody to α-tubulin. Panel A shows untreated (control) cells with delicate microtubule structures with only occasional mitotic elements. Panel B shows the addition of 50 µM AK295 to PC12 cells has little or no effect. Panel C shows cells 24 hours after treatment with paclitaxel (300 ng/ml). Microtubules are bundled (arrow) and there are frequent mitotic elements, indicating mitotic arrest. Panel D shows AK295 has no effect on tubulin bundling or mitotic arrest on PC12 cells treated with paclitaxel.

FIG. 8 is a bar graph showing results of a Sytox® assay for cell death in PC12 cells 24 hours after addition of paclitaxel (100 ng/ml). Higher fluorescence correlates with increased cell death. A) control; B) AK295 only; C) paclitaxel 100 ng/ml; D) paclitaxel 100 ng/ml and AK295 50 µM; E) paclitaxel 100 ng/ml and 3G36 (capsase-3 inhibitor) 50 µM; F) 3G36 only.

FIGS. 9A-B are line graphs showing clinical characteristics of rats with STZ diabetes. FIG. 9A shows mean blood glucose levels (normal 100 mg/dl). Diabetic animals did not gain weight, and there was no effect on weight of AK295 (bottom graph).

FIGS. 10A-D are bar graphs showing AK295 protects against diabetes-induced slowing of nerve conduction velocity and action potential amplitude. Data and p-values in chart. SCI=sciatic, CMAP=compound muscle action potential, SNAP=sensory nerve action potential amplitude, STZ-streptozotocin, IN=insulin treated, AK=AK295 treated.

FIGS. 11A-F are photomicrographs showing morphology and morphometry of sural nerve 8 weeks after treatment. There is little morphologic evidence of axonal degeneration, but morphometry demonstrates that AK295 protects against axonal atrophy. There is a trend toward more axons in the AK295 treated group.

FIGS. 12A and 12B are bar graphs showing dose dependent axonal degeneration in response to increasing levels of glucose.

FIGS. 13A-C are fluorescence photomicrographs of DRG cultures treated with glucose only (panel C) or glucose with AK295 (panel B). Panel A is the normal control showing the expected growth of axons over the experimental time period. Note the relative preservation of axons in the AK295 treated culture. Cultures treated for 8 days with 200 mM glucose, fixed and stained with MAP-5 axonal marker.

FIGS. 14A and B are bar graphs showing quantitative measure of relative protection of AK295 against high glucose-induced axonal degeneration at both 3 and 8 days after exposure.
The term "neurotoxin" refers to a compound that adversely affects cells of the nervous system. Suitable neurotoxins include compounds that induce axonal degeneration, for example by interfering with the neuronal cytoskeleton, in particular with microtubules. Microtubule stabilizers, for example Taxol® and Taccalonolides E and A, are preferred neurotoxins of the present invention. Taccalonolides E and A are described in Tinley T L et al. (2003) Taccalonolides E and A. Plant-derived steroids with microtubule-stabilizing activity. Cancer Res. June 15;63(12):3211-20, which is incorporated by reference in its entirety. Colchicine, colcemid, nocadazol, vinblastine and vincristine are additional exemplary neurotoxins that affect microtubules.

The term "Taxol®" is intended to be interchangeable with paclitaxel and refers to 5-beta,20-epoxy-1,2-alpha,4,7-beta,10-beta,13-alpha-hexahydroxy-tax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine; 7,11-Methano-5H-cyclocoscin(3,4)benz[1,2-b]oxaz-taxol; Taxol; Taxol A; substantially pure optical isomers, racemates, prodrugs, and derivatives thereof. The structure of paclitaxel is provided below.

The term "anti-hyperproliferative agent" means a substance that reduces, inhibits or interferes with aberrant cell growth or division. Exemplary anti-hyperproliferative agents include but are not limited to anti-cancer agents such as paclitaxel, chemotherapy agents, anti-sense polynucleotides, enzymatic polynucleotides, polypeptides, dideoxy nucleotides, chain terminating nucleotides, antibodies, and small molecules.

The term "hyperproliferative disorder" means a pathology resulting from aberrant cell growth or division.

The term "calpain related pathology" means an abnormal cellular or systemic condition or symptom directly or indirectly caused, in part or in whole, by the activity of a calpain protease.

The term "pharmacologically acceptable salt(s)", as used herein, unless otherwise indicated, includes salts of acidic or basic groups that may be present in the compounds of Formula I. The compounds of Formula I that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds of Formula I are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, TFA, pantethenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)] salts. Those compounds of the Formula I that are acidic in nature, are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline earth metal salts and particularly, the sodium and potassium salts.

The term "pharmacologically acceptable derivative" refers to any homolog, analog, or fragment corresponding to the peptide α-ketoamides of the present invention provided herein which inhibits protease activity and is relatively non-toxic to the subject or host.

The term "pharmacologically acceptable" means a material that is not biologically or otherwise undesirable, i.e., the material may be administered to an individual along with the selected bicyclic compound without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.

As used herein, and without limitation, the term "derivative" is used to refer to any compound which has a structure derived from the structure of the compounds of the present invention and whose structure is sufficiently similar to those disclosed herein and based upon that similarity, would be expected, by one skilled in the art, to exhibit the same or similar activities and utilities as the claimed compounds.

**Exemplary Embodiments**

Embodiments of the present invention describe compositions and methods for the treatment of a pathology, in particular a neural pathology such as cytoskeletal degeneration of peripheral neurons, peripheral neuropathy, or axonal degeneration including sensory neuron axonal degeneration. The neural pathology can be related to a disease or condition such as diabetes, or can be the result of contact with a chemical agent including neurotoxic agents. One of the several embodiments of the present invention provides a method for treating a neural pathology of the peripheral nervous system, for example axonal degeneration, by administering to a patient a therapeutically effective amount of a compound of the formula I:

\[ M^1 \text{-AA}^1 \text{-AA}^1 \text{-CO} \text{-NR}^1 \text{R}^1 \]

wherein

- \( M^1 \) is selected from the group consisting of \( H \), \( H_2 \text{-SO} \), \( H_2 \text{-CO} \), \( H_3 \text{-CS} \), \( H_3 \text{-SO}_2 \), \( X \text{-NH} \text{-CO} \), \( X \text{-NH} \text{-CS} \), \( X \text{-NH} \text{-SO} \), \( X \text{-N} \text{-SO} \), \( X \text{-CO} \), \( X \text{-CO} \), \( Y \text{-O} \text{-CO} \), \( Y \text{-O} \text{-CS} \), morpholine-CO, and biotinyl;
- \( X \) is selected from the group consisting of \( H \), \( C_{1-10} \text{-alkyl} \), \( C_{1-10} \text{-cycloalkyl} \), \( C_{1-10} \text{-fluoroalkyl} \), \( C_{1-10} \text{-alkyl substituted with } J \), \( C_{1-10} \text{-fluoroalkyl substituted with } J \), \( 1 \text{-adamantyl} \), 9-fluorenyl, phenyl, phenyl monosubstituted with K, phenyl disubstituted with K, phenyl trisubstituted with K, napthyl, and...
naphthyl monosubstituted with K, naphthyl disubstituted with K, naphthyl trisubstituted with K, C_{1-10} fluoroalkyl with an attached phenyl group, C_{1-10} alkyl with an attached phenyl group, C_{1-10} alkyl with two attached phenyl groups, C_{1-10} alkyl with an attached phenyl group substituted with K, C_{1-10} alkyl with two attached phenyl groups, C_{1-10} alkyl with an attached phenyl group substituted with K, C_{1-10} alkyl with an attached naphthyl group, C_{1-10} alkyl with an attached phenyl group attached to the alkyl, C_{1-10} alkyl with an attached phenyl group trisubstituted with K, C_{1-10} alkyl with an attached phenyl group disubstituted with K, C_{1-10} alkyl with an attached phenyl group substituted with K, C_{1-10} alkyl with a morpholine [-N(CH_{2}CH_{2})_{2}O] ring attached through nitrogen to the alkyl, C_{1-10} alkyl with a piperidine ring attached through nitrogen to the alkyl, C_{1-10} alkyl with an OH group attached to the alkyl, —CH_{2}CH_{2}OCH_{2}CH_{2}OH, C_{1-10} with an attached 4-pyridyl group, C_{1-10} with an attached 3-pyridyl group, C_{1-10} with an attached 2-pyridyl group, C_{1-10} with an attached cyclohexyl group, —NH—C_{1-10}(3-indolyl), —NH—C_{1-10}(4-hydroxyphenyl), —NH—C_{1-10}(3-indolyl); b) —CH_{2}Cl(OH)—R^{2}, and c) —(CH=CH)_{2}—R^{2}; R^{2} is selected from the group consisting of phenyl, phenyl monosubstituted with J, phenyl disubstituted with J, phenyl trisubstituted with J, pentafluorophenyl, 1-naphthyl, 1-naphthyl monosubstituted with J, 1-naphthyl disubstituted with J, 2-naphthyl, 2-naphthyl monosubstituted with J, 2-naphthyl disubstituted with J, 2-pyridyl, 2-quinolinyl, and 1-isoquinolinyl; R^{2} is selected from the group consisting of C_{1-10} alkyl, C_{1-10} alkyl substituted with phenyl, phenyl, and phenyl substituted with J; n=1-6; R^{2} is selected from the group consisting of C_{1-10} branched and unbranched alkyl, C_{1-10} branched and unbranched cyclicized alkyl, and C_{1-10} branched and unbranched fluoroalkyl; R^{2} and R^{3} are selected independently from the group consisting of...
Aspects of the present invention provide compositions and methods for treating neural pathologies by targeting axonal degeneration rather than by preventing the death of whole neurons or stimulating the growth of whole neurons. By inhibiting or preventing axonal degeneration, embodiments of the invention can maintain axonal connections between neurons and between neurons and their targets thereby preventing or reducing neuropathy. Axonal degeneration can occur over extended periods of time and, therefore, other embodiments of the invention are directed to compositions and methods for treating chronic pathologies resulting in axonal degeneration rather than rapid onset pathologies such as stroke.

The compounds of the present invention can be administered in an amount sufficient to inhibit, reduce, or ameliorate a pathology of the peripheral nervous system including but not limited to peripheral neuropathy, sensory neuron axonal degeneration, cytoskeletal degeneration of neurons of the peripheral nervous system, toxin-induced peripheral nerve cell damage, and calpain-related neuronal pathology. It will be appreciated by one of skill in the art that some embodiments of the present invention are directed to compositions and methods of treating pathologies of peripheral nervous system and not of the central nervous system.

Other embodiments of the invention describe compositions and methods for treating chronic degeneration of motor and or sensory neurons as may be seen in motor neuron diseases, peripheral neuropathies due to chronic systemic diseases (i.e., diabetes, uremia, liver diseases, infections, rheumatologic disorders), genetic mutations (hereditary motor/sensory and hereditary sensory neuropathy groups, including all Charcot-Marie-Tooth disorders), demyelinating neuropathies with secondary axonal degeneration (Guillain-Barre group) and idiopathic neuropathies, demyelinating disorders of the central nervous system including multiple sclerosis, and chronic spinal cord degenerations, genetically based and otherwise, comprising the step of administering to a patient a therapeutically effective amount of a compound of formula I.

Yet another embodiment of the invention provides a pharmaceutical composition including an anti-hyperproliferative agent in combination with a calpain inhibitor, for example a peptide α-ketoamide. Exemplary anti-hyperproliferative agents include microtubule stabilizing agents such as paclitaxel also referred to as Taxol®. Suitable peptide α-ketoamides include those of formula I. These compositions provide an anti-hyperproliferative effective amount of a anti-cancer agent with an effective amount of an agent for reducing the side effects associated with the anti-cancer agent. Thus, embodiments of the present invention disclose compositions comprising a combination of anti-cancer agents, for example paclitaxel, and peptide α-ketoamide calpain inhibitors. One of skill in the art will appreciate that the peptide α-ketoamide calpain inhibitors of the present invention do not directly treat hyperproliferative disorders, but instead, are used in combination with anti-cancer agents to minimize side effects of anti-cancer agents.

Still another embodiment of the present invention provides a method of treating a hyperproliferative disorder by administering a pharmaceutical composition comprising an anti-hyperproliferative agent in combination with a calpain inhibitor. Anti-hyperproliferative agents include microtubule stabilizing agents such as paclitaxel, and suitable calpain inhibitors include peptide α-ketoamides, for example AK295. AK295 is a potent transition-state reversible inhibitor for both calpain I (Kᵢ=0.14 µM) and calpain II (Kᵢ=0.041 µM), and is a less effective inhibitor of other cysteine proteases such as cathepsin B [Li, Z., A.-C. Ortega-Vilain, G. S. Patil, D.-L. Chu, J. E. Foreman, D. D. Eveleth and J. C. Powers (1996). "Novel peptidyl α-keto amide inhibitors of calpains and other cysteine proteases." J. Med. Chem. 39(20): 4089-4098.]. The calpain inhibitor can be administered concurrently with the anti-proliferative agent or subsequent to the administration of the anti-proliferative agent. Additionally, the calpain inhibitor can inhibit one or both of calpain I and calpain II.

Representative peptide α-ketoamides of the invention include but are not limited to:

\[
\begin{align*}
Z\text{-Leu-Nva-CO-}&-\text{NH-CH₂-2-pyridyl}, \\
Z\text{-Leu-Abu-CO-}&-\text{NH-CH₂CH(OH)C₆H₅P}, \\
Z\text{-Leu-Phe-CO-}&-\text{NH-(CH₃)₂Ph,} \\
Z\text{-Leu-Abu-CO-}&-\text{NH-CH₂CH(OH)C₆H₄₃-OC₆H₄(3-}\text{CF₃)}, \\
Z\text{-Leu-Abu-CO-}&-\text{NH-CH₂CH(OH)C₆H₄₃-OC₆H₄(4-OCH₃)Ph,} \\
Z\text{-Leu-Abu-CO-}&-\text{NH-CH₂CH(OH)C₆H₄₃(OH)Ph,} \\
Z\text{-Leu-Phe-CO-}&-\text{NH-CH₂-2-quinolinyl,} \\
Z\text{-Leu-Abu-CO-}&-\text{NH-(CH₃)₂C₆H₄(3-OC₆H₄)}, \\
Z\text{-Leu-Abu-CO-}&-\text{NH-(CH₃)₂C₆H₄(4-OCH₃)H,} \\
Z\text{-Leu-Abu-CO-}&-\text{NH-CH₂CH(OH)-1-C₆H₄H,} \\
Z\text{-Leu-Phe-CO-}&-\text{NH-(CH₃)₂4-morpholinyl,} \\
Z\text{-Leu-Abu-CO-}&-\text{NH-(CH₃)₂C₆H₄(2-OC₆H₄)}, \\
Z\text{-Leu-Abu-CO-}&-\text{NH-(CH₃)₂C₆H₄(2-quinolinyl),} \\
Z\text{-Leu-Abu-CO-}&-\text{NH-(CH₃)₂4-morpholinyl (AK295),} \\
Z\text{-Leu-Abu-CO-}&-\text{NH-(CH₃)₂-2-(N-methylpyrrole),} \\
Z\text{-Leu-Phe-CO-}&-\text{NH-CH₂CH(OH)C₆H₄(3-OC₆H₄(3-CF₃))}, \\
Z\text{-Leu-Abu-CO-}&-\text{NH-(CH₃)₂C₆H₅,} \\
Z\text{-Leu-Phe-CO-}&-\text{NH-Et,} \\
Z\text{-Leu-Abu-CO-}&-\text{NH-CH₂CH(OC₆H₄H)₂}, \\
\end{align*}
\]
Z-Leu-Phe-CO-NH-CH\_2-CH\_2CH(OH)C\_6H_4(3-OC\_6H_3(3,4-C\_l_2)),
Z-Leu-Abu-CO-NH-(CH\_2)_3-2-tetrahydroisoquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_5-OH,
Z-Leu-Abu-CO-NH-(CH\_2)_2-C\_6H_11,
Z-Leu-Phe-CO-NH-(CH\_2)_3-1-tetrahydroquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_2-3-indolyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-pyridyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-tetrahydroisoquinolinyl,
Z-Leu-Phe-CO-NH-Me,
Z-Leu-Phe-CO-NH-n-Pr,
Z-Leu-Phe-CO-NH-CH\_2-CH(OH)C\_6H_4(4-0CH_2Ph),
Z-Leu-Phe-CO-NH-CH\_2-Ch(OH)C\_6H_4-(3-C\_F_3),
Z-Leu-Phe-CO-NH-C\_6H_4(4-0CH_3),
Z-Leu-Phe-CO-NH-C\_6H_4(3-OC\_6H_3(3,4-Cl_2)),
Z-Leu-Phe-CO-NH-CH\_2-Ch(OH)C\_6H_4(3-C\_F_3),
Z-Leu-Phe-CO-NH-CH\_2-Ch(OH)C\_6H_4(3,4-Cl_2),
Z-Leu-Phe-CO-NH-(CH\_2)_3-OCH\_2Ph,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-tetrahydroisoquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-1-tetrahydroquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-pyridyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-tetrahydroisoquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-1-tetrahydroquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-pyridyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-tetrahydroisoquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-1-tetrahydroquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-pyridyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-tetrahydroisoquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-1-tetrahydroquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-pyridyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-tetrahydroisoquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-1-tetrahydroquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-pyridyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-tetrahydroisoquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-1-tetrahydroquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-pyridyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-tetrahydroisoquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-1-tetrahydroquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-pyridyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-tetrahydroisoquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-1-tetrahydroquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-pyridyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-tetrahydroisoquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-1-tetrahydroquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-pyridyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-tetrahydroisoquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-1-tetrahydroquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-pyridyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-tetrahydroisoquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-1-tetrahydroquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-pyridyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-tetrahydroisoquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-1-tetrahydroquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-pyridyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-tetrahydroisoquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-1-tetrahydroquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-pyridyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-tetrahydroisoquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-1-tetrahydroquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-pyridyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-2-tetrahydroisoquinolinyl,
Z-Leu-Phe-CO-NH-(CH\_2)_3-1-tetrahydroquinolinyl,
The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups, or elixirs. Dosage levels of the order of 0.2 mg to 140 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (10 mg to 7 gms per patient per day). The amount of active ingredient that may be combined with carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.

For injection, the therapeutic amount of the peptidase-keto­toamides or their pharmaceutically acceptable salts, derivatives or prodrugs will normally be in the dosage range from 0.2 to 140 mg/kg of body weight. Administration is made by intravenous, intramuscular, or subcutaneous injection. Accordingly, pharmaceutical compositions for parenteral administration will contain from about 10 mg to 7 gms of the compounds per dose. In addition to the active ingredient, these pharmaceutical compositions will usually contain a buffer, e.g. a phosphate buffer which keeps the pH in the range from 3.5 to 7 and sodium chloride, mannitol, or sorbitol for adjusting the isotonic pressure.

A composition for topical application can be formulated as an aqueous solution, lotion, jelly or an oily solution or suspension. A composition in the form of an aqueous solution is obtained by dissolving the compounds of this invention in aqueous buffer solution of pH 4 to 6.5 and, if desired, adding a polymeric binder. An oily formulation for topical application is obtained by suspending the compounds of this invention in an oil, optionally with the addition of a swelling agent such as aluminum stearate and/or a surfactant.

Materials and Methods

Paclitaxel-induced Axonal Degeneration in Rat DRG Culture

Dorsal Root Ganglion (DRG) from E15 rats were dissected and stripped from connective tissue into L15 medium (GIBCO), washed twice with PBS, and plated in collagen coated dishes containing DMEM with 1% N2 supplement and 7S NGF (100 ng/ml). Cultures were kept at 37°C, 5% CO2. After 5 days of growth, media was changed to that containing test agents (paclitaxel, AK 295), and DRG remained in culture for an additional 10 days. Paclitaxel was dissolved in Cremophor EL/ethanol (50:50); final concentration of Cremophor EL and ethanol was less than 0.0001%. AK295 was dissolved in DMSO with a final concentration of DMSO in culture of 0.05%. This amount of DMSO demonstrated no effects on DRG growth.

Serial Images of DRG were captured on day 0, 4, 8 and 10. The area of the DRG halo at each time point was normalized to the area measured on day 0 (day test agents added), enabling each DRG to serve as its own control. Data were subjected to ANOVA, with post-test correction for multiple comparisons.

Paclitaxel Neupathy and AK295 Treatment in Mice

Eight-week-old female C57BL/6J mice were separated into 4 treatment groups as outlined in FIG. 1. All groups were treated with paclitaxel and two groups were treated with a combination of paclitaxel and AK295. Three-week and 6-week protocols were investigated: paclitaxel was dissolved 50:50 in Cremophor EL/ethanol and diluted 1:1 with saline; final concentration was 7.5 mg/ml. Each paclitaxel treatment consisted of 3 injections of 60 mg/kg into the jugular vein on an every other day schedule. The 3-week groups received one paclitaxel treatment and the 6-week groups received two paclitaxel treatments. Control groups were treated with the Cremophor diluent only.

AK295 (Z-Leu-Abu-(CH2)n-4-morpholinyl) was synthesized as previously described [Li, Z., A.-C. Ortega-Vilain, G.

S. Patil, D.-L. Chu, J. E. Foreman, D. D. Eveleth and J. C. Powers (1996). “Novel peptidyl a-keto amide inhibitors of calpains and other cysteine proteases.” J. Med. Chem. 39(20): 4089-4098. The AK295 treatment groups received subcutaneous injections of AK295 (48 mg/kg) with each paclitaxel injection. After the last paclitaxel injection, a 100 µl Alzet pump (Alza Corporation, Mountain View, Calif.) filled with AK295 (84 mg/ml in DMSO/PEG 300, 1:1) was surgically implanted under the back skin. These pumps are designed to deliver drug at a rate of 6 µl per day for 14 days, translating into 0.504 mg/day, or 24 mg/kg/day for an average 18 g mouse. The 6-week treatment group received AK295 injections with the second paclitaxel treatment and had a new pump implanted for the remainder of the study. Control animals received initial injections with diluent only, and received pumps containing diluent only.

Animals were killed by perfusion with 4% paraformaldehyde (in 0.1M PBS buffer, pH 7.4) at the time points depicted in FIG. 1. The nerve roots (L4 dorsal and ventral) were harvested and post fixed overnight in 5% buffered glutaraldehyde at 4°C. Nerve roots were rinsed with PBS buffer, processed by standard methods, and embedded in plastic for light microscopy. Sections of 780 µm were stained with toluidine blue for microscopy study and image analysis.

Image Analysis

Images of dorsal and ventral roots (125x) were captured using a Kodak DCS-5 digital camera attached to an Olympus BH-2 microscope. Multiple overlapping images were captured, including all axons within the cross section. These images were combined into a montage so that the individual nerve fibers did not appear more than once. Images were analyzed using ImagePro software (Media Cybernetics, Silver Spring, Md.) running on a Gateway personal computer. All myelinated axons were counted. Axonal density was calculated by dividing the number of axons by the area of nerve cross-section. The diameter and area of each remaining axon was measured by tracing the inner border of myelin. All data were subjected to ANOVA.

Behavioral Testing

To evaluate changes in neuromuscular function, animals were subjected to testing on a Rotarod apparatus (Columbus Instruments, Columbus, Ohio) before paclitaxel treatments and prior to sacrifice. The initial speed was set at 1.6 rpm with acceleration rate of 4 rpm/min. Animals were acclimated to the Rotarod for three consecutive days before the test date. The test was repeated 3 times during each testing session with at least 2 minutes of rest between each test. The best performance of each session was recorded. Percent changes were calculated and analyzed using ANOVA with post-test comparisons.

Electrophysiology

Nerve conduction studies were performed using standard equipment (Nicolet, Madison, Wis.) on anesthetized animals on the same schedule as Rotarod testing. For hind limb recording, the recording electrodes were inserted into the interosseous muscles of the left foot; stimuli were administered at the ankle and at the hip (sciatric notch) close to the tibial and sciatic nerve, respectively. A ground electrode was inserted subcutaneously into the tail. Compound muscle action potential were recorded (maximum) and nerve conduction velocities were calculated. For tail nerve recording, the recording electrodes were placed at the base of the tail, keeping the anode and the cathode approximately 5 mm apart. Stimuli were administered 4-5 cm distal. A ground electrode was placed in between the stimulus and recording electrodes. The sensory nerve action potential was averaged over 50-80 stimuli, and the amplitude was recorded. Sensory conduction velocity was also calculated.
Calpain Activation Assay:
PC12 cells were grown for 24 hours in DMEM with 10% horse serum and 5% fetal calf serum. Calpain activity in response to paclitaxel was assessed in relation to dose (1, 10, 50, or 100 ng/ml for 24 hours) and of time of exposure (10 ng/ml of paclitaxel for up to 48 hours). After exposure, cells were suspended in KRH buffer (25 mM Na-HEPES, 115 mM NaCl, 5 mM KCl, 1 mM KH2PO4, 1.2 mM MgSO4, 2 mM CaCl2, 0.2% bovine serum albumin, pH 7.4) and 2 ml of cell suspension was transferred to test tube. The reaction was started by adding 100 µl of the cell-permeable calpain substrate (Suc-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin, final concentration 4 µM) and 50 µl of the experimental compounds (paclitaxel 10, 100, 200 or 100 ng/ml, AK295, 50 µM). The caspase inhibitor 13 (C30-A-S3G-Glu-Val-A-A-S3G-EP-CO3E) was synthesized in our laboratory. This caspase is highly active against caspase-3 and little activity against other cysteine proteases. (Aspian, J. L., E. James, Z. Z. Li, W. Carter, A. J. Barrett, J. M. W. Chen, and G. S. Savese and J. C. Powers 2002 “Aza-peptide epoxides: a new class of inhibitors selective for clan CD cysteine proteinases.” J. Med Chem 45(23); 4958-60.). Fluorescence (Ex 360 nm, Em 460 nm) was measured immediately and at scheduled time points for up to 24 hours. After the last reading, 50 µl of 4% paraformaldehyde was added to each well and the plate was kept at 4°C for one hour followed by a final reading for the maximal amount of fluorescence release. The experimental protocol was repeated three times.

EXAMPLES

Example 1

AK295 Protects Against Paclitaxel-induced Axon Degeneration in DRG Culture

Exposure to paclitaxel caused dose-dependent axonal degeneration in cultured dorsal root ganglia. Doses of 25 ng/ml or greater caused rapid axonal degeneration; a dose of 5 ng/ml did not cause obvious degeneration but did slow axonal growth (FIG. 2). Degeneration occurred in a distal to proximal pattern (“dying back”) similar to that seen in DRG cultures exposed to vincristine [Wang, M. S., Y. Wu, D. G. Culver and J. D. Glass 2000]. “Pathogenesis of axonal degeneration: parallels between Wallerian degeneration and vincristine neuropathy.” Journal of Neuropathology and Experimental Neurology 59(7): 599-606.). Addition of AK295 (50 µM) to the culture media provided about 50% protection against axonal degeneration induced by 25 ng/ml paclitaxel for up to 8 days, as measured by the area of the DRG halo (data not shown).

Example 2

AK295 Protects Against Paclitaxel Neuropathy in Mice

Paclitaxel caused dose-dependent axonal degeneration in mice. Two doses (3×30 mg/kg and 3×60 mg/kg) were tested. The low dose caused axonal degeneration in relatively few fibers, with inconsistent numbers of degenerating fibers (data not shown). The higher dose caused degeneration of a significant number of sensory fibers (FIG. 3A-F), which was reproducible and suitable for our purpose of quantitative analysis. Paclitaxel did not cause axonal degeneration in motor fibers.

Nineteen mice were used for the 3-week protocol: control (4), paclitaxel (7) and paclitaxel plus AK295 (8). Ten mice were used for the 6-week protocol: control (4), paclitaxel (3) and paclitaxel plus AK295 (3). The animals treated with paclitaxel or paclitaxel plus AK295 showed weight loss of 10-15% of baseline, whereas paclitaxel+AK295-treated mice showed weight loss of 2-3 grams in the first week, but regained a normal growth rate and were in good health for the remainder of the study (FIGS. 4A-C). Rotarod and electrophysiological measures supported the presence of peripheral neuropathy (FIG. 4), and pathological analysis of dorsal roots demonstrated significant loss of myelinated fibers at the 3-week time point (Table 1). There was little evidence of further progression of neuropathy in animals receiving a second paclitaxel treatment during the fourth week and evaluated at the 6-week time point. Pilot experiments, however, demonstrated almost full recovery of myelinated fiber numbers at 6 weeks in animals not receiving a second paclitaxel treatment (data not shown), suggesting that the second paclitaxel treatment had the effect of maintaining the neuropathy in animals that otherwise would have recovered. Analysis of fibers grouped by diameter demonstrated that axonal loss was most prominent in larger fibers (FIGS. 5A-D), as has been demonstrated in paclitaxel neuropathy in humans and rats.

AK295 treatment was protective against paclitaxel-induced neuropathy by all measures. Behavioral and electrophysiological testing showed protection in the AK295 group at 3 weeks that persisted to 6-week time point (FIGS. 4A-D). Comparing pre- and post-treatment measures, animals treated with diluent only improved by about 20% on the Rotarod (not shown), whereas performance in Paclitaxel-treated mice was reduced to about 60% of baseline. Paclitaxel+AK295-treated mice remained at baseline levels. Similar results were obtained from sensory nerve conduction studies. Tail SNAP in Paclitaxel-treated mice was reduced to about 50% of baseline, whereas paclitaxel+AK295-treated mice showed no reduction in sensory amplitudes. There were no significant effects of paclitaxel on motor conduction studies in either sciatic or tail nerves (not shown).

Pathologically, the degree of axonal degeneration was less in AK295-treated mice as compared to mice treated with paclitaxel only (FIGS. 3A-F and Table 1). Quantitative analysis demonstrated an increase in fiber number and density at both 3 and 6 weeks in the AK295 group (Table 1). Mean fiber diameter was also increased toward normal in these groups (Table 1). Subgroup analysis of the effects of paclitaxel and AK295 by fiber size demonstrated the large-fiber predominance of paclitaxel toxicity and the relative protection by AK295 in these larger fibers (FIGS. 5A-D).
Cultured DRG from E15 rats were also exposed to various levels of glucose in order to test the protection of AK295 against axonal degeneration due to glucose toxicity (FIGS. 12A-B and FIGS. 13A-C).

In these whole animal and cell culture models of diabetes-related neuropathy we show that there is protection by AK295 against measures of nerve function (conduction velocity and nerve amplitude), and protection against axonal degeneration (FIGS. 14A-B).

**Example 3**

Paclitaxel-induced Calpain Activation in PC12 Cells

PC12 cells were used to demonstrate that exposure to paclitaxel can induce calpain activation and that AK295 inhibits calpain activity. In PC12 cells there was both time and dose-dependent increase in calpain activity as measured by cleavage of a synthetic calpain substrate (FIGS. 6A-B). AK295 inhibited calpain-mediated cleavage of the substrate. It is of interest to note that AK295 reduced the baseline calpain activity measured in non-treated cells as well, without causing any apparent toxicity.

**Example 4**

Paclitaxel-induced Tubulin Aggregation and Cell Death

The antineoplastic effects of paclitaxel are based on its capacity to bind and stabilize microtubules, leading to mitotic arrest, activation of caspases and cell death. We were concerned that inhibition of calpains with AK295 might interfere with Paclitaxel-mediated cell death. To address this issue we used PC12 cells to assess the effect of AK295 on the formation of tubulin bundles and caspase-mediated cell death in response to paclitaxel exposure. PC12 cells showed aggregation of α-tubulin after exposure to paclitaxel with or without addition of AK295 (FIGS. 7A-D). The frequency of mitotic arrest was also unchanged in cells treated with AK295. The Sytox® cytotoxicity assay showed cell death after exposure to paclitaxel that was unaffected by the presence of AK295 (FIG. 8). Addition of a caspase-3 inhibitor reduced cell death to control levels.

**Example 5**

Calpain Inhibition with AK295 in a Model of Diabetic Neuropathy

AK295 was tested for its ability to modify the clinical and pathological features of diabetes mellitus-related peripheral neuropathy. Wistar rats (male, 9 weeks old) were treated with a single dose (75 mg/kg iv) of the pancreatic toxin streptozotocin (STZ), causing them to become diabetic (FIGS. 9A-B). This was an 8-week study with 4 groups: 1) control (no STZ), 2) STZ only, 3) STZ+Insulin, 4) STZ+Insulin+AK295 (FIGS. 10A-D, FIGS. 11A-F, and Tables 2 and 3). Insulin was given 2x/week based on the measurement of serum glucose at a dose of 8µg/100 mg/dl. AK295 as provided as a continuous subcutaneous infusion via pump at a dose of 20 mg/kg/day based on a 300 gram rat.

---

**TABLE 1**

<table>
<thead>
<tr>
<th>Morphometry of dorsal root axons, mean ± SEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Groups</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>Control, 3 w</td>
</tr>
<tr>
<td>Paclitaxel, 3 w</td>
</tr>
<tr>
<td>Paclitaxel + AK295, 3 w</td>
</tr>
<tr>
<td>Control, 6 w</td>
</tr>
<tr>
<td>Paclitaxel, 6 w</td>
</tr>
<tr>
<td>Paclitaxel + AK295, 6 w</td>
</tr>
</tbody>
</table>

*p < 0.05, paclitaxel + AK295 vs. paclaxel only. 3 w = 3 weeks, 6 w = 6 weeks.

---

**TABLE 2**

<table>
<thead>
<tr>
<th>treatment</th>
<th>Sci CMAP</th>
<th>Sci NCV</th>
<th>Tail SNAP</th>
<th>Tail NCV</th>
</tr>
</thead>
<tbody>
<tr>
<td>control</td>
<td>19.88 ± 5.20</td>
<td>31.33 ± 1.29</td>
<td>27.64 ± 3.93</td>
<td>51.67 ± 1.45</td>
</tr>
<tr>
<td>STZ</td>
<td>20.43 ± 7.92</td>
<td>33.00 ± 4.04</td>
<td>37.61 ± 11.05</td>
<td>32.00 ± 2.08</td>
</tr>
<tr>
<td>STZ + insulin</td>
<td>10.99 ± 0.40</td>
<td>33.67 ± 1.76</td>
<td>41.52 ± 0.46</td>
<td>34.33 ± 1.86</td>
</tr>
<tr>
<td>STX</td>
<td>16.32 ± 2.34</td>
<td>47.00 ± 4.04</td>
<td>71.33 ± 14.39</td>
<td>40.00 ± 1.00</td>
</tr>
<tr>
<td>STX + insulin + AK</td>
<td>0.04</td>
<td>0.04</td>
<td>0.005</td>
<td>0.028</td>
</tr>
</tbody>
</table>

---

**TABLE 3**

<table>
<thead>
<tr>
<th>Morphometric analysis of aural nerve after 8 weeks treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Groups</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>control</td>
</tr>
<tr>
<td>STZ + insulin</td>
</tr>
<tr>
<td>STX + insulin + AK</td>
</tr>
</tbody>
</table>

---

**TABLE 4**

<table>
<thead>
<tr>
<th>Calpain Inhibition Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>M1</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Z</td>
</tr>
</tbody>
</table>
Axonal degeneration is a feature common to a wide spectrum of neurologic disorders and axonal degeneration is the pathology that underlies clinical dysfunction in these disorders. These diseases include peripheral neuropathies due to genetic mutations, peripheral neuropathies associated with other systemic diseases including uremia, rheumatologic diseases, liver diseases, and infections, axonal degeneration secondary to primary demyelinating disorders including inflammatory demyelinating neuropathies and multiple sclerosis. These α-ketoamide calpain inhibitors will be effective in preventing axonal degeneration in these other disorders and will thus constitute a novel treatment for these diseases.

The above specification and Examples fully disclose how to make and use the methods of the present invention. However, the present invention is not limited to the particular embodiments described herein, but includes all modifications thereof within the scope of the following claims. The various references to journals, patents, and other publications which are cited herein comprise the state of the art and are incorporated herein by reference.

**TABLE 4-continued**

<table>
<thead>
<tr>
<th>M</th>
<th>AA</th>
<th>R²</th>
<th>Cal I</th>
<th>Cal II</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z</td>
<td>Abu</td>
<td>CH₂-t-isoquinolinyl</td>
<td>0.25</td>
<td>0.15</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>Et</td>
<td>0.25</td>
<td>0.21</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>CH₂(C(OH)CH₂)₃-OC₆H₃(3,4-CF₃)</td>
<td>0.27</td>
<td>0.12</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>Me</td>
<td>0.28</td>
<td>0.083</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>(CH₂)₂-tetrahydroquinolinyl</td>
<td>0.29</td>
<td>0.066</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>(CH₂)₂-3-indolyl</td>
<td>0.3</td>
<td>0.05</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>(CH₂)₂-tetrahydroisocinokinolyl</td>
<td>0.31</td>
<td>0.19</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>CH₂-2-tetrahydrofuryl</td>
<td>0.33</td>
<td>0.086</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>CH₂(CH₂)₆H₂(4-N(CH₃)₂)</td>
<td>0.33</td>
<td>0.41</td>
</tr>
<tr>
<td>Z</td>
<td>Phe</td>
<td>n-P</td>
<td>0.35</td>
<td>0.05</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>CH₂(CH(OH)CH₂)₂</td>
<td>0.35</td>
<td>0.11</td>
</tr>
<tr>
<td>Z</td>
<td>Phe</td>
<td>Me</td>
<td>0.35</td>
<td>0.15</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>CH₂(CH(OH)CH₂)₃-OC₆H₃(3-CF₃)</td>
<td>0.35</td>
<td>0.18</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>(CH₂)₁-tetrahydroquinolinol</td>
<td>0.37</td>
<td>0.2</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>CH₂(C₂H₅)₃(4-OH)</td>
<td>0.38</td>
<td>0.06</td>
</tr>
<tr>
<td>Z</td>
<td>Phe</td>
<td>CH₂(CH(OH)CH₂)₃(3-CF₃)</td>
<td>0.46</td>
<td>0.29</td>
</tr>
<tr>
<td>Z</td>
<td>Phe</td>
<td>CH₂(CH(OH)CH₂)(3,4-OCH₂CH₂)</td>
<td>0.47</td>
<td>0.26</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>CH₂(2-pyridyl)</td>
<td>0.41</td>
<td>0.47</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>CH₂-C₆H₄(1,3-(CH₂)₆-5-OH)</td>
<td>0.42</td>
<td>0.069</td>
</tr>
<tr>
<td>Z</td>
<td>Phe</td>
<td>CH₂(CH(OH)CH₂)₃(3-CF₃)</td>
<td>0.46</td>
<td>0.29</td>
</tr>
<tr>
<td>Z</td>
<td>Phe</td>
<td>CH₂(CH(OH)CH₂)(3,4-OCH₂CH₂)</td>
<td>0.47</td>
<td>0.67</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>CH₂(2-pyridyl)</td>
<td>0.5</td>
<td>0.031</td>
</tr>
<tr>
<td>Z</td>
<td>Phe</td>
<td>CH₂(CH(OH)CH₂)(3,4-CF₃)</td>
<td>0.5</td>
<td>0.1</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>CH₂(C₆H₅C₂H₄)(3-0CH₂Ph)</td>
<td>0.59</td>
<td>0.12</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>CH₂(CH(OH)CH₂)(3-0Ph)</td>
<td>0.6</td>
<td>0.34</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>CH₂(CH(OH)CH₂)(4-0CH₂Ph)</td>
<td>0.62</td>
<td>0.31</td>
</tr>
<tr>
<td>Z</td>
<td>Phe</td>
<td>CH₂(2-pyridyl)</td>
<td>0.64</td>
<td>0.017</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>(CH₂)₂-OH</td>
<td>0.65</td>
<td>0.16</td>
</tr>
<tr>
<td>Z</td>
<td>Phe</td>
<td>CH₂-2-pyridyl</td>
<td>0.65</td>
<td>0.27</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>(CH₂)₂-NH-biotinyl</td>
<td>0.65</td>
<td>0.28</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>CH₂-C₆H₄</td>
<td>0.68</td>
<td>0.044</td>
</tr>
<tr>
<td>Z</td>
<td>Phe</td>
<td>CH₂(CH(OH)CH₂)₅</td>
<td>0.7</td>
<td>0.13</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>CH₂-2-arylm</td>
<td>0.8</td>
<td>0.033</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>CH₂(C₂H₅)₃(4-OH)</td>
<td>0.8</td>
<td>0.043</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>CH₂-OH</td>
<td>0.8</td>
<td>0.078</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>CH₂(CH(OH)CH₂)(3-0Ph)</td>
<td>0.9</td>
<td>0.59</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>(CH₂)₁-4-morpholinyl</td>
<td>1</td>
<td>0.16</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>CH₂(CH(OH)CH₂)Ph</td>
<td>1</td>
<td>0.015</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>CH₂-4-pyridyl</td>
<td>1</td>
<td>0.11</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>(CH₂)₁-1-pyrrolidine-2-one</td>
<td>1.2</td>
<td>0.27</td>
</tr>
<tr>
<td>Z</td>
<td>Phe</td>
<td>CH₂(CH(OH)CH₂)Ph</td>
<td>1.3</td>
<td>0.05</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>CH₂CH₂H₂(3,5-OCH₂CH₂)</td>
<td>2.3</td>
<td>0.022</td>
</tr>
<tr>
<td>Z</td>
<td>Nva</td>
<td>CH₂(CH(OH)Ph)</td>
<td>7.8</td>
<td>11</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>CH₂-8-salicylilin</td>
<td>32</td>
<td>4.6</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>n-Pr</td>
<td>0.25</td>
<td>0.25</td>
</tr>
<tr>
<td>Z</td>
<td>Abu</td>
<td>CH₂-3-pyridyl</td>
<td>0.12</td>
<td>0.064</td>
</tr>
<tr>
<td>Z</td>
<td>Phe</td>
<td>CH₂Ph</td>
<td>0.046</td>
<td>0.064</td>
</tr>
</tbody>
</table>

What is claimed is:

1. A method for treating axonal degeneration of the peripheral nervous system of a patient comprising administering to the patient a compound selected from the group consisting of:

- Z-Leu-Nva-CO—NH—CH₂-2-pyridyl,
- Z-Leu-Abu-CO—NH—CH₂(CH(OH)CH₂)₃(CF₃),
- Z-Leu-Phe-CO—NH—(CH₂)₂Ph,
- Z-Leu-Abu-CO—NH—CH₂(CH(OH)CH₂)₃(4-OCH₂Ph),
- Z-Leu-Abu-CO—NH—CH₂(CH(OH)CH₂)₃(4-OPh),
- Z-Leu-Phe-CO—NH—CH₂-2-quinolinol,
- Z-Leu-Abu-CO—NH—(CH₂)₂C₆H₄(3-OCH₃),
- Z-Leu-Abu-CO—NH—(CH₂)₂C₆H₄(3-OCH₂Ph),
- Z-Leu-Phe-CO—NH—(CH₂)₂C₆H₄(3-OCH₂Ph),
- Z-Leu-Phe-CO—NH—(CH₂)₂C₆H₄(2-OCH₃),
- Z-Leu-Abu-CO—NH—(CH₂)₂-2-(N-methylpyrrole),
- Z-Leu-Phe-CO—NH—CH₂(CH(OH)CH₂)₃(3-CF₃),
- Z-Leu-Abu-CO—NH—(CH₂)₂C₆H₄, 
- Z-Leu-Phe-CO—NH—(CH₂)₂C₆H₄,
21. Z-Leu-Phe-CO—NH—CH₂-2-pyridyl,
Z-Leu-Abu-CO—NH—(CH₂)₂NH-biotinyl,
Z-Leu-Abu-CO—NH—CH₂-C₆H₅,
Z-Leu-Phe-CO—NH—CH₂CH(OH)C₆F₅,
Z-Leu-Abu-CO—NH—CH₂-2-furyl,
Z-Leu-Abu-CO—NH—(CH₂)₃C₆H₃,
Z-Leu-Abu-CO—NH—(CH₂)₂OH,
Z-Leu-Abu-CO—NH—CH₂CH(OH)C₆H₄(3-OPh),
Z-Leu-Abu-CO—NH—(CH₂)₄-morpholinyl,
Z-Leu-Abu-CO—NH—(CH₂)₄-pyridyl,
Z-Leu-Abu-CO—NH—(CH₂)₄-pyrrolidine-2-one,
Z-Leu-Phe-CO—NH—CH₂CH(OH)Ph,
Z-Leu-Abu-CO—NH—CH₂C₆H₃(3,5-(OCH₃)₂),
Z-Leu-Nva-CO—NH—CH₂CH(OH)Ph,
Z-Leu-Abu-CO—NH—CH₂-8-caffeiny1,
Z-Leu-Abu-CO—NH-n-Pr,

22. Z-Leu-Abu-CO—NH—CH₂-3-pyridyl,
Z-Leu-Phe-CO—NH—CH₂Ph, and
Z-Leu-Abu-CONH—(CH₂)₄-morpholinyl;
wherein Z is a benzyloxycarbonyl group.

2. The method of claim 1, wherein the compound is Z-Leu-Abu-CONH—(CH₂)₄-morpholinyl.

3. The method of claim 1, wherein the axonal degeneration of the peripheral nervous system is chemically-induced axonal degeneration.

4. The method of claim 1, wherein the compound is administered concurrently with an anti-hyperproliferative agent.

5. The method of claim 1, wherein the compound is administered subsequent to administration of an anti-hyperproliferative agent.

6. The method of claim 1, wherein the compound is administered orally.

* * * * *